Who Owns Haleon After the GSK-Pfizer Consumer Health Split

Haleon is a new company that was formed after the split of GSK-Pfizer Consumer Health. It's a significant development in the healthcare industry.

Haleon was created in January 2022 through a 50/50 joint venture between GlaxoSmithKline (GSK) and Pfizer. This partnership was formed to create a leading consumer health company.

The joint venture was announced in 2021, and the separation was completed on January 1, 2022.

You might enjoy: Who Owns Magellan Health

Haleon plc was formed as a spin-off from GlaxoSmithKline (GSK) in July 2022. This separation allowed GSK to focus on its pharmaceuticals and vaccines business while Haleon concentrated on consumer health products.

Haleon was valued at approximately £30 billion at the time of its separation. It inherited a portfolio of well-known brands, including Sensodyne, Panadol, and Voltaren, which contributed to its significant market presence.

The company operates in more than 100 markets worldwide and has a workforce of about 22,000 employees. Its first year of independent operations saw revenue of £10.4 billion for the fiscal year 2022.

Here's a breakdown of Haleon's ownership structure:

Former parent company GSK retains a minority interest in Haleon, owning about 15% of the total shares following the spin-off.

Haleon plc was formed as a spin-off from GlaxoSmithKline (GSK) in July 2022. This separation allowed GSK to focus on its pharmaceuticals and vaccines business while Haleon concentrated on consumer health products.

Haleon was valued at approximately £30 billion at the time of its separation. Its portfolio of well-known brands contributed significantly to its market presence.

The company operates in more than 100 markets worldwide and has a workforce of about 22,000 employees. This global reach enables Haleon to cater to diverse consumer needs.

Haleon's revenue for its first year of independent operations was £10.4 billion for the fiscal year 2022. This was a growth compared to GSK's consumer health division's revenue of £9.2 billion in 2021.

Here's a brief financial overview of Haleon's first two years of operation:

Haleon's strategic initiatives include expanding its product range and investing in digital health solutions. In 2022, the company allocated approximately £500 million to research and development, focusing on innovation in oral health and pain relief products.

A Haleon Plc was spun off from GlaxoSmithKline (GSK) in July 2022, marking a significant change in the company's ownership structure. This spin-off resulted in Haleon becoming a global consumer health company.

Approximately 75% of Haleon's shares are held by institutional investors, with major asset management firms like Vanguard Group and BlackRock holding significant stakes. Individual investors comprise about 5% of the total ownership.

The remaining 15% of shares are held by GSK, the company's former parent. This minority interest gives GSK a significant influence over Haleon's strategic decisions.

Haleon's ownership structure is dominated by institutional investors, with a significant portion retained by GSK. This will continue to impact the company's market performance in the evolving consumer health landscape.

Here's a breakdown of the major institutional shareholders:

Haleon's market capitalization was approximately £30 billion shortly after the separation from GSK.

Haleon, the largest company to list in London for over a decade, has made its market debut as a result of the consumer health spin-off from GSK and Pfizer.

The company's name, Haleon, is pronounced 'Hay-lee-on' and is inspired by the merging of the words 'hale', meaning 'in good health' in old English, and 'leon', associated with the word strength as it is Spanish for lion.

Haleon's revenues are divided between oral health, digestive health and pain relief, and other sectors such as respiratory health, with sales of £9.5bn last year.

The company will be led by chief executive Brian McNamara, who has been CEO of the division since 2016 and spent the previous two-and-a-half decades focused on consumer health at Novartis and Procter & Gamble.

Haleon's board will be guided by former Tesco boss Sir Dave Lewis as chair.

The ownership structure of Haleon reflects both institutional and individual investors, as well as its former parent company.

Here is a breakdown of the major institutional shareholders and their respective percentages:

Haleon's market capitalization was approximately £30 billion shortly after the separation from GSK, and its stock price hovered around £3.00 per share as of early October 2023.

Shares in Haleon are scheduled to start trading on Monday 18 July, making it London's largest stock market listing in a decade.

The demerger was approved with overwhelming support from investors, with 99.8% voting in favour of the move.

Each GSK investor will receive one share in Haleon for each share they own in the parent company.

Haleon will be seeking an enterprise valuation of as much as £45bn and an equity value of £33.1bn.

At least 54.5% of Haleon will be held by GSK shareholders, 13.5% by GSK itself, and 32% by Pfizer.

Pfizer announced it planned to exit its 32% ownership interest in Haleon in June, aiming to ‘maximise value for Pfizer shareholders’.

Brian McNamara will lead the new company, while former Tesco chief executive Sir Dave Lewis will be chairman of the board.